Editorial: Efficacy of Additional Solifenacin Succinate Therapy in Females with Urinary Tract Infection

Urinary tract infection (UTI) is a collective word for diseases involving any portion of the urinary tract and it’s the most common infection in local primary care that has suffered from it by up to 60 percent of females and has at least one symptomatic UTI in a lifetime. UTI can have consequences like kidney infection, infections of the urinary tract, and, eventually, toxic septicemia. UTI is often confused with wide-spectrum antibiotics, so it is imperative to characterize resistance patterns to enhance in-vitro antibiotic strategies. According to previous studies, the use of anticholinergics to relieve UTI symptoms has never been investigated. This research is the first randomized trial of anticholinergic-like solifenacin succinate (with a strong affinity for smooth muscle receptors M3) to treat and improve UTI.